Background: Treatment modalities of acromegaly and disease control impact differently on glucose homeostasis and lipid changes, and consequently on cardiometabolic risk. Aim: To investigate the possible association of lipid profile changes with the glycemic control status in acromegaly patients treated with octreotide LAR. Methods: This cross-sectional study included 52 Iraqi patients with acromegaly treated with octreotide LAR and not using statins. Demographic, anthropometric, and clinical data were collected, as well as the duration of Octreotide LAR administration. The glycemic state was assessed and classified as DM, prediabetes, or normal. Plasma levels of triglycerides, LDL cholesterol, HDL cholesterol, and non-HDL were evaluated using standard methods. Results: Most of the participants presented with low levels of triglycerides, LDL cholesterol, and HDL cholesterol. The lipid profile variables were not significantly correlated with the glycemic control status after treatment with octreotide LAR. Conclusion: Lipid profile parameters were not associated with the different glycemic control status of acromegaly patients treated with octreotide LAR.
